-
Phase 1
-
-
18-55Age Range
-
1Locations
-
Recruiting
Recruiting
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.
Inclusion Criteria: - Body mass index between 18 and 30 kilograms/meter squared inclusive, at the screening visit. - Japanese participants must be of Japanese descent (both biological parents are ethnically Japanese). - Caucasian participants must be of European or Latin American Caucasian descent. - A female participant is eligible to participate if she is a woman of nonchildbearing potential as defined in the protocol. - Males who are sexually active with woman of childbearing potential must agree to follow protocol-defined instructions for method(s) of contraception. Exclusion Criteria: - Any acute or chronic medical illness. - Active infection, including with coronavirus disease-19, diagnosed clinically by the investigator. - History of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or sponsor clinical trial physician, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. Note: Other protocol-defined inclusion/exclusion criteria apply.
Experimental: Caucasian Cohort - Dose 3
Experimental: Japanese Cohort - Dose 1
Experimental: Japanese Cohort - Dose 2
Experimental: Japanese Cohort - Dose 3